EU MDR Authorized Representative: A Practical Guide (2026)

What an EU MDR Authorized Representative actually is

The EU MDR Authorized Representative — commonly called the EC REP, European Authorized Representative, or simply AR — is the EU-resident legal entity designated by a non-EU medical device manufacturer to act as their regulatory interface with EU competent authorities. The role is defined in Article 11 of EU Regulation 2017/745 (MDR) and its IVDR counterpart, Article 11 of Regulation 2017/746.

The EC REP is not a distributor. It is not a sales representative. It is not a commercial agent. It is a regulatory-compliance function with specific legal responsibilities, and combining it with commercial functions can create conflicts of interest that the regulation explicitly anticipates.

Who needs one — and who doesn't

Under MDR Article 11(1), every manufacturer that places a device on the EU market and is not established in the EU must designate a single Authorized Representative. "Established in the EU" means having a registered place of business in an EU member state — not merely having a sales presence or distribution agreement.

Practical implications:

• US manufacturer with European customers: needs EC REP.
• UK manufacturer post-Brexit: needs EC REP (UK is no longer EU).
• Swiss manufacturer: needs EC REP for EU markets, plus a separate CH-REP for Switzerland.
• Asian, Australian, or LatAm manufacturer: needs EC REP.
• EU-headquartered manufacturer: does not need an EC REP. The legal manufacturing entity in the EU fulfills the equivalent function directly.

The "single Authorized Representative" wording is important. A manufacturer cannot appoint multiple EC REPs (e.g., one for Germany, one for France). One EC REP covers all EU member states for that manufacturer's full device portfolio. This is a notable change from earlier directive-based regimes that allowed country-by-country representatives.

The 8 legal responsibilities under Article 11

MDR Article 11(3) defines the specific tasks of the EC REP. These are not optional services to negotiate — they are mandatory minimum responsibilities:

1. Verify the EU Declaration of Conformity and technical documentation have been drawn up and applicable conformity assessment procedures completed.
2. Maintain a copy of the technical documentation, the Declaration of Conformity, and (where applicable) the Notified Body certificate, available for competent authorities upon request.
3. Comply with registration obligations for the manufacturer in EUDAMED (and, until EUDAMED is fully operational, in national databases).
4. Verify UDI assignment for the device.
5. Cooperate with competent authorities on any preventive or corrective action including market surveillance investigations.
6. Forward complaints and reports from healthcare professionals, patients, or users about suspected incidents related to the device.
7. Terminate the mandate if the manufacturer acts contrary to MDR obligations — and inform the competent authority and Notified Body.
8. Verify the manufacturer's compliance with PMS and PMCF obligations.

Joint liability — the under-discussed clause

Article 11(5) is the clause that most non-EU manufacturers under-appreciate when signing EC REP agreements. The wording (in EU legalese) means that the EC REP is jointly and severally liable with the manufacturer for defective devices placed on the EU market on the same basis as the manufacturer, under national civil-liability rules.

The implication: a defective device that causes patient harm in Germany can result in the EC REP being sued alongside the manufacturer in German court. The EC REP cannot contractually escape this — it is a legal liability imposed by the regulation, not an optional contractual term.

This explains several market realities:

• EC REP service fees include liability insurance pass-through. Reputable EC REPs carry substantial product liability insurance specifically for their EC REP portfolio. The annual premium is reflected in their service pricing.
• EC REPs are selective about which manufacturers they take on. A small unknown manufacturer with limited regulatory history will face higher pricing or outright refusal compared to an established manufacturer with strong technical files.
• Class III implantable devices command premium EC REP pricing. The liability exposure is higher; the technical documentation is more complex; the post-market vigilance burden is heavier.

How to choose an EC REP — selection criteria

EC REP services are offered by three broad types of providers:

1. Specialized regulatory consulting firms

Companies like Emergo by UL, Obelis, Qserve, MedNet, and Donawa Lifescience offer EC REP services as part of broader regulatory consulting practices. Strengths: deep regulatory expertise, large portfolios, established relationships with competent authorities. Weaknesses: pricing is at the higher end; you may be one of hundreds of clients.

2. Small/medium independent EC REP firms

Smaller independents focused primarily on EC REP services. Strengths: more attentive service, often more cost-effective for single-device or small portfolios, faster response times. Weaknesses: smaller insurance pools, less name recognition with Notified Bodies and authorities.

3. Your EU distributor or subsidiary

If you have an EU-resident distributor partner with regulatory capacity (or you have set up a small EU subsidiary), they can serve as your EC REP. Strengths: integrated regulatory and commercial relationship, single contact point. Weaknesses: conflict of interest (the distributor's incentive to keep selling can conflict with the EC REP's duty to terminate the mandate if compliance fails); reduced regulatory expertise compared to specialized providers.

The contract terms that matter

The EC REP mandate (the formal written agreement) should at minimum address the following terms. Manufacturers who skip these later find themselves in difficult positions during audits or compliance incidents:

• Scope of devices covered. Specific device list with UDIs, not a vague "all current and future products" clause.
• Term and termination. Minimum notice periods for either party. Note: under Article 11(7), the EC REP must inform the competent authority of termination immediately, which can create market-exit complications.
• Technical documentation access. The EC REP needs ongoing access to the current technical file. Define the format (cloud-shared, encrypted portal, regular updates).
• Vigilance reporting protocols. Who reports what to whom, within what timelines, and using which template.
• Indemnification and insurance. Each party's product liability insurance levels; mutual indemnification for the other party's negligence.
• Fee structure. Annual base fee, per-device fee, per-transaction fee for vigilance reports or competent authority requests.
• Dispute resolution. Governing law (typically the EC REP's home country), arbitration vs. litigation, forum selection.
• Confidentiality and data protection. GDPR-compliant handling of any patient or user data shared.

Realistic cost ranges

EC REP service pricing varies by device class, portfolio breadth, and provider type. Typical 2026 ranges:

• Class I: €1,500 – €4,000 per year
• Class IIa, single device: €3,000 – €7,000 per year
• Class IIb, single device: €5,000 – €12,000 per year
• Class III non-implantable: €8,000 – €20,000 per year
• Class III implantable: €15,000 – €40,000 per year
• Multi-device portfolios: typically priced with a base fee plus per-device increments, with significant economies of scale for portfolios of 10+ devices.

Set-up fees (initial document review, registration setup) are typically 50–100% of the first-year annual fee. Vigilance reporting and competent authority response work is sometimes billed hourly above an included annual allocation.

When the distributor is also the EC REP — pros and cons

For small medical device companies entering Europe, a common arrangement is to designate their EU distributor as the EC REP as well. The MDR does not prohibit this, but it carries specific risks worth understanding.

Pros

• Single contractual relationship simplifies management.
• Distributor often already handles vigilance, complaints, and technical documentation in practice.
• Lower aggregate cost than separate EC REP service.

Cons

• Conflict of interest at termination. Under Article 11(7), the EC REP must terminate the mandate if the manufacturer acts contrary to MDR. A distributor-EC REP has strong commercial incentive to not terminate even when warranted.
• Liability concentration. The distributor carries both commercial and regulatory liability, increasing their exposure and potentially their insurance costs.
• Switching costs. Changing distributors becomes much more complex if they are also the EC REP — you must transfer technical documentation, re-register, and notify competent authorities of the change.
• Geographic coverage. A single-country distributor may not have the regulatory infrastructure or relationships to handle competent authority interactions across multiple EU markets.

Switzerland CH-REP and UK Responsible Person

Two adjacent markets require their own representative roles distinct from the EU EC REP:

Switzerland — CH-REP

Since the EU-Switzerland Mutual Recognition Agreement on medical devices lapsed in May 2021, manufacturers selling into Switzerland require a Swiss Authorized Representative (CH-REP). This is a separate appointment from the EU EC REP — your EU EC REP cannot serve dual duty unless they have a Swiss-resident entity.

United Kingdom — UK Responsible Person (UKRP)

Post-Brexit, non-UK manufacturers placing devices on the Great Britain market require a UK Responsible Person (UKRP). This is similar in function to the EU EC REP and is registered with MHRA. Northern Ireland continues to accept CE-marked devices under the Windsor Framework, so for NI-only sales an EU EC REP is sufficient.

A medical device manufacturer with full European ambition (EU + Switzerland + UK) needs:

1. One EU EC REP (covers 27 EU member states)
2. One CH-REP (covers Switzerland)
3. One UKRP (covers Great Britain)

Some larger regulatory consulting firms offer bundled tri-jurisdiction services through their EU, Swiss, and UK entities. This is operationally convenient but does not eliminate the requirement for three distinct legal appointments.

Operational pitfalls and how to avoid them

From observed compliance incidents and Notified Body audit feedback, the recurring operational pitfalls in EC REP arrangements:

1. EC REP details missing or wrong on labeling

MDR Article 27(7) requires the EC REP's name and address on the device label or IFU. Missing or incorrect EC REP details on labeling is one of the most common findings in market surveillance inspections. Verify periodically that current labeling matches your current EC REP mandate.

2. Technical file not updated at EC REP

EC REPs must hold the current technical documentation. After design changes, IFU updates, or PMS revisions, manufacturers often forget to send the updated documentation to the EC REP. Build the documentation hand-off into your change-control SOPs.

3. Vigilance reports lost in handoff

Complaints from healthcare professionals often go directly to the manufacturer, who must then forward to the EC REP for competent authority reporting. Missed handoffs cause late reporting, which is a regulatory finding. Establish clear notification protocols and audit them.

4. EC REP terminating during a sales-critical moment

If your EC REP terminates the mandate (e.g., due to non-payment, scope dispute, or perceived compliance issue), all devices placed on the market without a current EC REP become non-conforming. This can trigger immediate market withdrawal. Maintain backup EC REP relationships or short-notice transition agreements.

5. EUDAMED registration drift

The EC REP is responsible for EUDAMED registration accuracy. Manufacturer changes (legal entity, address, contact persons) must be reflected in EUDAMED. Drift creates inspection findings; sync EUDAMED data with manufacturer records quarterly.

Where this fits in your European market entry

The EC REP is a regulatory cornerstone for any non-EU medical device manufacturer entering Europe. It is not, however, a complete go-to-market function. You still need country-specific distribution partners, reimbursement strategy, clinical KOL relationships, and hospital procurement capability — all of which are commercial functions outside the EC REP's scope.

The directory at MedicalDeviceDistributors.com covers the distribution side — finding the partners who will sell your device into European hospitals once your regulatory pathway and EC REP are in place. For end-to-end market entry support combining regulatory navigation with distributor selection and contract negotiation, see Fractio.